All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PT001
Therapeutic Area: Immunology Product Name: PT001
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
The research, done in collaboration with St Vincent’s Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $180.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 03, 2021
Details:
Imcyse and Pfizer will collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis. Pfizer will lead clinical development and commercialization activities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IL233
Therapeutic Area: Immunology Product Name: IL233
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Epidarex Capital
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Financing January 19, 2021
Details:
Financing will support development of novel IL-2 treatments for various diseases. IL233, Slate's lead candidate, is a first in class drug that induces persistent remission in animal models of autoimmune and inflammatory diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Jubilant Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed